DO-BO

How Will the EU JCA Reshape National HTA Across Europe, Dr. Oriol Solà-Morales?

Is the EU Joint Clinical Assessment just another administrative layer, or the start of a truly European HTA?

In this MAP episode, Dr. Stefan Walzer talks with Dr. Oriol Solà-Morales, physician, health economist, founder and CEO of HITT and founding member of EUnetHTA, about what the first JCA reports reveal.

Drawing on Spain’s shift from regional to coordinated HTA, Oriol sees the JCA’s potential to build Europe. He describes a deliberately conservative start: concise PICO consolidation, uncertainties named but not resolved, and a clear line between the European assessment and national reimbursement decisions. They discuss how countries like Germany may gradually adapt, for example on indirect comparisons and progression-free survival, and why JCA requirements belong in development planning by the end of phase I. Success, in his view, means more transparency and a stable, predictable environment for development in Europe.

Connect with Oriol on LinkedIn: https://www.linkedin.com/in/oriol-sol%C3%A0-morales-a130692/

Related

AI is reshaping health economics and outcomes research (HEOR) – but where does it truly belong? In this MAP episode, Dr. Stefan Walzer talks with Haidong Feng, Associate Principal Scientist at Merck, about “human in the loop” versus “AI in the loop” and why the two complement rather than contradict each other. Haidong explains why […]

When the US benchmarks drug prices against other countries, the whole world feels it. In this episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Brittany La Couture of Applied Policy, a health policy attorney with eight years at the Centers for Medicare & Medicaid Services, to unpack the US […]

In this episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Rainer Westermann, Chairman of the Life Sciences Acceleration Alliance (LSAA), to ask whether Europe can remain a globally competitive home for life sciences innovation — and what has to change for new therapies to reach patients. Bringing an investor’s […]